Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.

SG&A Trends: Jazz vs. Travere Over a Decade

__timestampJazz Pharmaceuticals plcTravere Therapeutics, Inc.
Wednesday, January 1, 201440611400059644696
Thursday, January 1, 201544911900079541000
Friday, January 1, 201650289200098015000
Sunday, January 1, 2017544156000103958000
Monday, January 1, 2018683530000103654000
Tuesday, January 1, 2019736942000128951000
Wednesday, January 1, 2020854233000135799000
Friday, January 1, 20211451683000149883000
Saturday, January 1, 20221416967000220206000
Sunday, January 1, 20231343105000265542000
Loading chart...

Unleashing insights

A Decade of SG&A: Jazz Pharmaceuticals vs. Travere Therapeutics

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Jazz Pharmaceuticals plc and Travere Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals has seen a significant increase, with expenses growing by approximately 230% from 2014 to 2023. This rise reflects their aggressive expansion and strategic investments. In contrast, Travere Therapeutics, while also experiencing growth, has maintained a more conservative trajectory, with SG&A expenses increasing by around 345% over the same period. This difference highlights the varied strategic approaches of these companies. Jazz's peak in 2021, with expenses reaching nearly 1.45 billion, contrasts with Travere's steady climb to 266 million in 2023. These insights offer a glimpse into the operational strategies that shape the competitive landscape of the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025